TGF-beta1 siRNA suppresses the tubulointerstitial fibrosis in the kidney of ureteral obstruction.

[1]  J. Rossi,et al.  Amplification of RNAi--targeting HLA mRNAs. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[2]  Z. Zhigang,et al.  Ex vivo transfer of the decorin gene into rat glomerulus via a mesangial cell vector suppressed extracellular matrix accumulation in experimental glomerulonephritis. , 2005, Experimental and molecular pathology.

[3]  K. Meldrum,et al.  Inflammatory mediators and growth factors in obstructive renal injury. , 2004, The Journal of surgical research.

[4]  T. Du,et al.  Asymmetry in the Assembly of the RNAi Enzyme Complex , 2003, Cell.

[5]  Young-Chae Chang,et al.  Inhibitory effects of novel E2F decoy oligodeoxynucleotides on mesangial cell proliferation by coexpression of E2F/DP. , 2003, Biochemical and biophysical research communications.

[6]  Zuoshang Xu,et al.  An enhanced U6 promoter for synthesis of short hairpin RNA. , 2003, Nucleic acids research.

[7]  K. Cutroneo.  How is Type I procollagen synthesis regulated at the gene level during tissue fibrosis , 2003, Journal of cellular biochemistry.

[8]  T. Shirakawa,et al.  Blockade of TGF-beta action ameliorates renal dysfunction and histologic progression in anti-GBM nephritis. , 2003, Kidney international.

[9]  B. Eyden,et al.  The ultrastructure of human tubulo-interstitial fibrosis. , 2003, Journal of submicroscopic cytology and pathology.

[10]  S. Hubchak,et al.  TGF-β signal transduction and mesangial cell fibrogenesis , 2003 .

[11]  D. Corey,et al.  Enhanced strand invasion by peptide nucleic acid-peptide conjugates. , 2002, Biochemistry.

[12]  P. Opolon,et al.  Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. , 2002, Biochemical and biophysical research communications.

[13]  K. Hruska.  Treatment of chronic tubulointerstitial disease: a new concept. , 2002, Kidney international.

[14]  W. Forrester,et al.  A DNA vector-based RNAi technology to suppress gene expression in mammalian cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[15]  R. Bernards,et al.  A System for Stable Expression of Short Interfering RNAs in Mammalian Cells , 2002, Science.

[16]  Titia Sijen,et al.  On the Role of RNA Amplification in dsRNA-Triggered Gene Silencing , 2001, Cell.

[17]  Q. Wei,et al.  RNAi as Random Degradative PCR siRNA Primers Convert mRNA into dsRNAs that Are Degraded to Generate New siRNAs , 2001, Cell.

[18]  P. Sharp,et al.  RNA interference--2001. , 2001, Genes & development.

[19]  T. Tuschl,et al.  RNA interference is mediated by 21- and 22-nucleotide RNAs. , 2001, Genes & development.

[20]  J. Erickson,et al.  Evidence that processed small dsRNAs may mediate sequence-specific mRNA degradation during RNAi in Drosophila embryos , 2000, Current Biology.

[21]  H. E. Hansen,et al.  The Banff 97 working classification of renal allograft pathology. , 1999, Kidney international.

[22]  S. Dedhar,et al.  Integrin-linked Protein Kinase Regulates Fibronectin Matrix Assembly, E-cadherin Expression, and Tumorigenicity* , 1998, The Journal of Biological Chemistry.

[23]  E. Imai,et al.  Application of gene therapy to diabetic nephropathy. , 1997, Kidney international. Supplement.

[24]  W. Border,et al.  Transforming growth factor-β in human glomerular injury , 1997 .

[25]  W. Border,et al.  TGF-β in kidney fibrosis: A target for gene therapy , 1997 .

[26]  Y. Kaneda,et al.  Inhibition of TGF-beta 1 expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis. , 1996, Kidney international.

[27]  C. Nast,et al.  Expression of transforming growth factor-β isoforms in human glomerular diseases , 1996 .

[28]  E. Ritz,et al.  PDGF and TGF-β contribute to the natural course of human IgA glomerulonephritis , 1995 .

[29]  K. Sharma,et al.  Role of transforming growth factor-beta in diabetic glomerulosclerosis and renal hypertrophy. , 1995, Kidney international. Supplement.

[30]  W. Couser,et al.  Mechanisms of progressive renal disease in glomerulonephritis. , 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[31]  E. Ruoslahti,et al.  Elevated expression of transforming growth factor-beta and proteoglycan production in experimental glomerulonephritis. Possible role in expansion of the mesangial extracellular matrix. , 1990, The Journal of clinical investigation.

[32]  N. Wardle.  Glomerulosclerosis: the final pathway is clarified, but can we deal with the triggers? , 1996, Nephron.